Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Isis Pharmaceuticals has earned $3.5m in milestone payment from Massachusetts-based drugmaker Biogen Idec related with the dosing of the first patient in the second phase study of ISIS-SMNRx in infants with spinal muscular atrophy (SMA).
Subscribe to our email newsletter
IISIS-SMNRxis designed to alter the splicing of a closely related gene (SMN2) to increase production of fully functional SMN protein.
As per the terms of January 2012 agreement, Isis is responsible for the global development and Biogen Idec has the option to license the compound ISIS-SMNRx until completion of the first successful Phase 2/3 study.
The US Food and Drug Administration (FDA) has granted orphan drug status and fast track designation to ISIS-SMN for the treatment of patients with SMA.
The second phase study of ISIS-SMNRx is an open-label, multiple-dose, dose-escalation pilot study, which will include eight infants who are between the ages of three weeks and seven months and diagnosed with SMA.
The study will be conducted at centers in the US and Canada.